Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.59 |
| ▸ | MAOA | P21397 | 1/20 | 0.59 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.59 |
| ▸ | SCN4A | P35499 | 1/20 | 0.59 |
| ▸ | BLM | P54132 | 1/20 | 0.59 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.59 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.59 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.59 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.59 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.59 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.59 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.59 |
| ▸ | PTPN11 | Q06124 | 19/20 | 0.58 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29542922 | 1.00 | MAPK1 (0.59) | MAPK1CYP2D6MAOAADRA1ASCN4A | |
| SCHEMBL29041371 | 0.87 | MAPK1 (0.55) | MAPK1CYP2D6MAOAADRA1ASCN4A | |
| SCHEMBL30296174 | 0.87 | MAPK1 (0.55) | MAPK1CYP2D6MAOAADRA1ASCN4A | |
| SCHEMBL976695 | 0.87 | SCN2A (0.62) | MAPK1CYP2D6MAOAADRA1ASCN4A | |
| SCHEMBL20788774 | 0.84 | PTPN11 (0.46) | MAPK1CYP2D6MAOAADRA1ASCN4A | |
| SCHEMBL25649854 | 0.84 | PTPN11 (0.62) | MAPK1CYP2D6MAOAADRA1ASCN4A | |
| SCHEMBL30990515 | 0.84 | PTPN11 (0.46) | MAPK1CYP2D6MAOAADRA1ASCN4A | |
| SCHEMBL7061215 | 0.80 | PTPN11 (0.73) | MAPK1CYP2D6MAOAADRA1ASCN4A | |
| SCHEMBL20811241 | 0.80 | PTPN11 (0.56) | MAPK1CYP2D6MAOAADRA1ASCN4A | |
| SCHEMBL28967328 | 0.80 | MAPK1 (0.52) | MAPK1CYP2D6MAOAADRA1ASCN4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3571199-B1 | BICYCLIC COMPOUNDS AS ALLOSTERIC SHP2 INHIBITORS | REVOLUTION MEDICINES INC (US) | 2026-04-22 | — | — | EP | disclosed |
| US-20260103469-A1 | BICYCLIC COMPOUNDS AS ALLOSTERIC SHP2 INHIBITORS | REVOLUTION MEDICINES INC (US) | 2026-04-16 | — | — | US | disclosed |
| US-12565476-B2 | 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric SHP2 inhibitors | Revolution Medicines, Inc. (US) | 2026-03-03 | — | — | US | disclosed |
| US-12365688-B2 | Substituted pyrazolopyrazines, imidazopyrazines and [1,2,4]triazolopyrazines as allosteric SHP2 inhibitors | Revolution Medicines, Inc. (US) | 2025-07-22 | — | — | US | disclosed |
| US-12331056-B2 | SHP2 phosphatase inhibitors and methods of use thereof | RELAY THERAPEUTICS, INC. (US) | 2025-06-17 | — | — | US | disclosed |
| EP-4506035-A2 | SHP2 PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | Relay Therapeutics, Inc. (US) | 2025-02-12 | — | — | EP | disclosed |
| US-12084447-B2 | SHP2 phosphatase inhibitors and methods of use thereof | RELAY THERAPEUTICS, INC. (US) | 2024-09-10 | — | — | US | disclosed |
| EP-3768668-B1 | SHP2 PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS INC (US) | 2024-08-28 | — | — | EP | disclosed |
| CN-111201223-B | Octahydrocyclopenta [ c ] pyrrole allosteric inhibitors of SHP2 | 克鲁松制药公司 | 2024-07-09 | — | — | CN | disclosed |
| US-20240199616-A1 | BICYCLIC COMPOUNDS AS ALLOSTERIC SHP2 INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2024-06-20 | — | — | US | disclosed |
| US-20170015680-A1 | N-AZASPIROCYCLOALKANE SUBSTITUTED N-HETEROARYL COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF SHP2 | NOVARTIS AG (CH) | 2017-01-19 | — | — | US | disclosed |
| US-20170015680-A1 | N-AZASPIROCYCLOALKANE SUBSTITUTED N-HETEROARYL COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF SHP2 | NOVARTIS AG (CH) | 2017-01-19 | — | — | US | disclosed |
| WO-2015107495-A1 | N-AZASPIROCYCLOALKANE SUBSTITUTED N-HETEROARYL COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF SHP2 | NOVARTIS AG (CH) | 2015-07-23 | — | — | WO | disclosed |
| WO-2015107493-A1 | 1 -PYRIDAZIN-/TRIAZIN-3-YL-PIPER(-AZINE)/IDINE/PYROLIDINE DERIVATIVES AND AND COMPOSITIONS THEREOF FOR INHIBITING THE ACTIVITY OF SHP2 | NOVARTIS AG (CH) | 2015-07-23 | — | — | WO | disclosed |
| EP-0966448-B1 | PYRAZINE COMPOUNDS | GLAXO GROUP LTD (GB) | 2003-10-01 | — | — | EP | disclosed |
| US-6599905-B2 | Phenyl or naphthyl-pyrazine compounds useful in the treatment of central nervous system diseases | SMITHKLINE BEECHAM CORPORATION | 2003-07-29 | — | — | US | disclosed |
| US-20020169172-A1 | Pyrazine compounds | GLAXO WELLCOME INC. | 2002-11-14 | — | — | US | disclosed |
| US-6255307-B1 | CENTRAL NERVOUS SYSTEM DISORDERS; ANTICONVULSANTS | GLAXO WELLCOME, INC. | 2001-07-03 | — | — | US | disclosed |
| EP-0966448-A1 | PYRAZINE COMPOUNDS | GLAXO GROUP LIMITED (GB) | 1999-12-29 | — | — | EP | disclosed |
| WO-1998038174-A1 | PYRAZINE COMPOUNDS | GLAXO GROUP LIMITED (GB) | 1998-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240199616-A1 | BICYCLIC COMPOUNDS AS ALLOSTERIC SHP2 INHIBITORS | PTPN18, PTPN1, PTPN2 | MAPK1 482/4885CYP2D6 3457/4885MAOA 4775/4885 |
| US-20020169172-A1 | Pyrazine compounds | HCRTR1, HCRTR2, GRIN2C | MAPK1 1501/4885CYP2D6 260/4885MAOA 981/4885 |
| US-12365688-B2 | Substituted pyrazolopyrazines, imidazopyrazines and [1,2,4]triazolopyrazines as allosteric SHP2 inhibitors | PTPN5, PTPN2, PTPN1 | MAPK1 307/4885CYP2D6 2744/4885MAOA 4503/4885 |
| US-12084447-B2 | SHP2 phosphatase inhibitors and methods of use thereof | PTPRCAP, PTPN22, PTPN1 | MAPK1 458/4885CYP2D6 4137/4885MAOA 4100/4885 |
| US-20260103469-A1 | BICYCLIC COMPOUNDS AS ALLOSTERIC SHP2 INHIBITORS | PTPN5, PTPN6, PTPN1 | MAPK1 579/4885CYP2D6 1416/4885MAOA 4305/4885 |
| US-20170015680-A1 | N-AZASPIROCYCLOALKANE SUBSTITUTED N-HETEROARYL COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF SHP2 | PTPN5, PTPN1, PTPN7 | MAPK1 457/4885CYP2D6 1476/4885MAOA 1853/4885 |
| US-12331056-B2 | SHP2 phosphatase inhibitors and methods of use thereof | PTPRCAP, PTPN22, PTPN1 | MAPK1 458/4885CYP2D6 4137/4885MAOA 4100/4885 |
| US-12565476-B2 | 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric SHP2 inhibitors | PTPN5, PTPN6, PTPN2 | MAPK1 453/4885CYP2D6 1488/4885MAOA 4417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.